Drug treatment of arrhythmias -- cosmetics of the ECG or benefit to the patient
Toivonen, L.; Heikkilä, J.
Annals of Clinical Research 19(1): 1-4
1987
ISSN/ISBN: 0003-4762 PMID: 3579199 Document Number: 292852
Document emailed within 1 workday
Related Documents
Toivonen, L.; Heikkilä, J. 1986: Drug therapy of arrhythmia--ECG, a "cosmetic" or benefit to the patient? Duodecim; Laaketieteellinen Aikakauskirja 102(22): 1651-1661Gardner, J. 1999: Pharmacists join drug benefit debate. if Medicare offers prescription drug benefit, pharmacists want to be reimbursed Modern Healthcare 29(49): 6
Greuner-Sigusch, P. 1978: Drug treatment of bradycardial arrhythmias Therapie der Gegenwart 117(4): 565-572
Lumholtz, I.B. 1980: Drug information: agents for the treatment of cardiac arrhythmias. 1 Sygeplejersken 80(22): 26
Lumholtz, I.B. 1981: Drug information: agents for the treatment of arrhythmias. Therapeutic main group: anti-arrhythmia agents. 16. (3). Anti-arrhythmia agents with action on ventricular arrhythmias Sygeplejersken 81(2): 15
Batlle, F.; Carreño, C.A.; Guetta, N.J.; Vassolo, E.; Bertolasi, C.A. 1970: Treatment of cardiac arrhythmias using a beta adrenergic receptor blocking drug Prensa Medica Argentina 57(38): 1801-1808
Pieterse, A.H.; Stalmeier, P.F.; Kroep, J.R.; Stiggelbout, A.M. 2011: Adjuvant cancer treatment: what benefit does the patient consider worthwhile? Nederlands Tijdschrift Voor Geneeskunde 155(45): A3905
Kurz, A. 2006: Study questions the benefit of the treatment. Aggressive Alzheimer patient -- a (not a) case for atypical neuroleptics? MMW Fortschritte der Medizin 148(47): 16
Lumholtz, I.B. 1980: Drug information: agents for the treatment of arrhythmias. Therapeutic main group: anti-arrhythmia agents. 14. Digitalis glycosides Sygeplejersken 80(50): 13
Pazdur, R. 2006: PROs: defining clinical benefit from the patient's perspective. Draft guidance provides direction in evaluating patient-reported outcomes Oncology 20(6): 660
Wåhlin, S. 2010: Health services of today benefit from increased patient centered care. Focus on the patient yields effective care--but there is also room for paternalism Lakartidningen 107(44): 2726-2728
Wagner, L. 1989: Drug benefit underfunded--report Modern Healthcare 19(20): 26
Lessem, J.N.; Hamby, R.A. 1986: Therapy of drug-resistant ventricular arrhythmias Fortschritte der Medizin 104(41): 784-786
Höpp, H.W.; Kochs, M.; Hilger, H.H. 1988: Drug therapy of tachycardic ventricular arrhythmias Medizinische Klinik 83(23): 800-808
Wilensky, G.R. 2006: Implementing the Medicare drug benefit--the first 90 days Healthcare Financial Management: Journal of the Healthcare Financial Management Association 60(6): 42-43
Bower, P. 2009: Drug prevention of hypertension. All cause absolute benefit? Bmj 338: B2597
Cundiff, D.K. 2003: Medicare prescription drug benefit realities Medgenmed: Medscape General Medicine 5(4): 28
Scott, L. 1995: AmHS to negotiate drug-benefit alliance Modern Healthcare 25(40): 10
Penna, P. 2004: Outcomes research in the Medicare drug benefit Managed Care Interface 17(1): 19-20
Erich, J. 2000: Amiodarone: the AHA's new drug of choice for victims of ventricular arrhythmias Emergency medical services 29(10): 22